Committed to transforming the treatment of severe blood disorders

Global Blood Therapeutics, Inc. (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in adults and adolescents. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF), and hereditary angioedema (HAE).

Year Invested: 2012
Location: South San Francisco, Calif.

Recent News

February 16, 2017
Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions

February 14, 2017
Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters

January 18, 2017
Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease

Read More News

Associated Team Members

Kevin Starr

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.

Glenn Pierce, M.D., Ph.D.